Cardiovascular risks associated with beta-agonist therapy.
Murray
John J
JJ
D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality* / Q000503:physiopathology; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate
D000318:Adrenergic beta-Agonists